Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation bias? V Cagno, ED Tseligka, ST Jones, C Tapparel Viruses 11 (7), 596, 2019 | 356 | 2019 |
Biocompatible Zr-based nanoscale MOFs coated with modified poly (ε-caprolactone) as anticancer drug carriers M Filippousi, S Turner, K Leus, PI Siafaka, ED Tseligka, M Vandichel, ... International Journal of Pharmaceutics 509 (1-2), 208-218, 2016 | 128 | 2016 |
A VP1 mutation acquired during an enterovirus 71 disseminated infection confers heparan sulfate binding ability and modulates ex vivo tropism ED Tseligka, K Sobo, L Stoppini, V Cagno, F Abdul, I Piuz, P Meylan, ... PLoS pathogens 14 (8), e1007190, 2018 | 66 | 2018 |
Antiviral drug screening by assessing epithelial functions and innate immune responses in human 3D airway epithelium model B Boda, S Benaoudia, S Huang, R Bonfante, L Wiszniewski, ED Tseligka, ... Antiviral research 156, 72-79, 2018 | 59 | 2018 |
Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation bias? Viruses 11: 596 V Cagno, ED Tseligka, ST Jones, C Tapparel | 28 | 2019 |
HDV pathogenesis: unravelling ariadne’s thread ED Tseligka, S Clément, F Negro Viruses 13 (5), 778, 2021 | 26 | 2021 |
Pharmacological development of target-specific delocalized lipophilic cation-functionalized carboranes for cancer therapy ED Tseligka, A Rova, EP Amanatiadou, G Calabrese, J Tsibouklis, ... Pharmaceutical research 33, 1945-1958, 2016 | 22 | 2016 |
Boron-containing delocalised lipophilic cations for the selective targeting of cancer cells C Gianpiero, D Anis, R Aikaterini, T Eirini, VS Ioannis, FG Dimitrios, ... MedChemComm 8 (1), 67-72, 2017 | 20 | 2017 |
Development and Pharmacological Evaluation of New Bone-Targeted 99mTc-Radiolabeled Bisphosphonates G Makris, ED Tseligka, I Pirmettis, MS Papadopoulos, IS Vizirianakis, ... Molecular Pharmaceutics 13 (7), 2301-2317, 2016 | 17 | 2016 |
Growth of Zika virus in human reconstituted respiratory, intestinal, vaginal and neural tissues V Cagno, ED Tseligka, Q Bettex, S Huang, S Constant, C Tapparel Clinical Microbiology and Infection 25 (8), 1042. e1-1042. e4, 2019 | 8 | 2019 |
Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias? Viruses. 2019; 11 (7): 596 V Cagno, ED Tseligka, ST Jones, C Tapparel | 8 | |
Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation bias? Viruses 11 (7): 596 V Cagno, ED Tseligka, ST Jones, C Tapparel | 7 | 2019 |
Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias? Viruses. 2019; 11: 596 C Tseligka, J Tapparel | 5 | |
Variant enterovirus A71 found in immune-suppressed patient binds to heparan sulfate and exhibits neurotropism in B-cell-depleted mice KF Weng, HK Tee, ED Tseligka, V Cagno, G Mathez, S Rosset, ... Cell reports 42 (4), 2023 | 3 | 2023 |
Formulation and characterisation of spray-dried o-carborane/poly (vinylpyrrolidone) for boron neutron capture therapy of liver and lung cancer J Smith, T Olusanya, AJS Owens, ED Tseligka, IS Vizirianakis, ... Journal of Innovations in Pharmaceutical and Biological Sciences 4 (4), 9-15, 2017 | 3 | 2017 |
Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation Bias? Viruses. 11 (2019) 596 V Cagno, ED Tseligka, ST Jones, C Tapparel | 3 | |
ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistance D Gomes, C Sobolewski, S Conzelmann, T Schaer, E Lefai, D Alfaiate, ... Scientific Reports 13 (1), 6767, 2023 | 2 | 2023 |
Identification of selective hepatitis delta virus ribozyme inhibitors by high-throughput screening of small molecule libraries ED Tseligka, S Conzelmann, Y Cambet, T Schaer, F Negro, S Clément JHEP Reports 5 (3), 100652, 2022 | 2 | 2022 |
Identification of novel antivirals against hepatitis delta virus infection via high throughput screening E Tseligka, S Clément-Leboube, F Negro Journal of Hepatology 77, S877, 2022 | | 2022 |
Identification of Enterovirus 71 Virulence Determinants E Tseligka éditeur non identifié, 2019 | | 2019 |